Skip to main content

Phathom Pharmaceuticals, Inc.

corporate_fare Company Profile

Phathom Pharmaceuticals, Inc.

PHAT·NASDAQ·Life Sciences·CIK 0001783183

We are a commercial-stage biopharmaceutical company focused on commercializing and developing new treatments for gastrointestinal (GI) diseases. Our approved products, VOQUEZNA®, VOQUEZNA® DUAL PAK®, and VOQUEZNA® TRIPLE PAK®, contain vonoprazan. Vonoprazan is an oral small molecule potassium-competitive acid blocker (PCAB), a class of molecules that block acid secretion in the stomach. VOQUEZNA is the only PCAB approved for marketing and sale in the United States. We began U.S. commercialization of VOQUEZNA for erosive gastroesophageal reflux disease (Erosive GERD) and Helicobacter pylori (H. pylori) infection, and VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK for H. pylori infection, in November 2023. The U.S. Food and Drug Administration (FDA) approved VOQUEZNA for heartburn associated with Non-Erosive GERD in July 2024. Vonoprazan was originally developed by Takeda Pharmaceutical Company Limited and is marketed in multiple countries outside the United States. We licensed U.S., European, and Canadian rights to vonoprazan from Takeda in 2019. We independently commercialize VOQUEZNA, VOQUEZNA DUAL PAK, and VOQUEZNA TRIPLE PAK in the United States. For the year ended December 31, 2025, we generated increased revenues from sales of our VOQUEZNA products compared to the prior year, with the majority of 2025 revenue from VOQUEZNA sales. During this period, we saw growth in prescription volume and prescriber adoption, with most prescriptions for GERD indications. As of February 13, 2026, over 1.1 million prescriptions for our VOQUEZNA products have been filled since launch. We have broad commercial coverage for VOQUEZNA, with access for over 120 million, or over 80%, of U.S. commercial lives.

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for PHAT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-29, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for PHAT spans 8-K, 10-Q, 10-K, 424B5.

Recent high-impact activity:

  • Phathom Q3 Revenue Jumps 71% to $84.7M; Second Straight Quarter of Positive Operating Cash Flow
  • Q3 Revenue Jumps 71% to $84.7M as Phathom Turns Adjusted Profit, Reaffirms Guidance
  • FDA Opens Comment Docket on VOQUEZNA Exclusivity Fight; Second ANDA Filer Emerges
  • FDA Opens Public Docket on VOQUEZNA Exclusivity as ANDA Fight Escalates
  • Generic Rival Sues FDA to Break VOQUEZNA Exclusivity Running to 2032

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$175.11M
Net Income
-$221.25M
Diluted EPS
-$3.03
Op. Cash Flow
-$166.78M
Free Cash Flow
-$167M
Gross Profit
$152.51M
Operating Income
-$159.99M
Cash & Equivalents
$129.97M
Total Debt
$209.09M
Debt / Equity
-0.48×
Net Margin
-126.3%
Shares Outstanding
71.42M sh
Source: 10-K · filed 2026-02-26 · accession 0001193125-26-073379

Short Interest & Short Volume

4.83 days to cover

FINRA reported short interest of 9,204,035 shares in PHAT as of the October 30, 2026 settlement, a 5.9% decrease from the prior period — about 4.8 days to cover at its recent average daily volume. On November 20, 2026, 52.9% of PHAT volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)9,204,035 shares as of October 30, 2026
Change vs prior period▼ 5.9%
Days to cover4.83 at avg daily volume of 1,903,950
Daily short volume (FINRA facilities)52.9% of 447,233 shares on November 20, 2026
5-day average short volume46.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with P →
$4.66
52-week range · as of 2026-10-29 $4.66 – $18.31
Market cap
$378.82M
Volume
1.3M (0.8× avg)
3-mo avg 1.7M
Live data · 2026-11-21 17:40 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PHAT - Latest Insights

PHAT
Oct 29, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.65
Real-time Price: $4.66 info
Change: -$1.99 (-30%) info
Market Cap: $378.819M info
PHAT
Oct 29, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $6.65
Real-time Price: $4.66 info
Change: -$1.99 (-30%) info
Market Cap: $378.819M info
PHAT
Oct 26, 2026, 6:02 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.50
Real-time Price: $4.66 info
Change: -$0.840 (-15%) info
Market Cap: $378.819M info
PHAT
Oct 26, 2026, 4:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $5.50
Real-time Price: $4.66 info
Change: -$0.840 (-15%) info
Market Cap: $378.819M info
PHAT
Oct 23, 2026, 4:00 AM EDT
Source: Wiseek News
Importance Score:
8
Updated Oct 23, 5:02 PM ET — Phathom said FDA correctly evaluated the issue in its June 6, 2025 grant of Phathom's December 11, 2024 Citizen Petition recognizing 10 yea…
Price at Filing: $6.86
Real-time Price: $4.66 info
Change: -$2.20 (-32%) info
Market Cap: $378.819M info
PHAT
Sep 29, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.30
Real-time Price: $4.66 info
Change: -$2.64 (-36%) info
Market Cap: $378.819M info
PHAT
Jul 30, 2026, 7:18 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $11.30
Real-time Price: $4.66 info
Change: -$6.64 (-59%) info
Market Cap: $378.819M info
PHAT
Jul 30, 2026, 7:05 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $11.40
Real-time Price: $4.66 info
Change: -$6.74 (-59%) info
Market Cap: $378.819M info
PHAT
Jul 30, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $11.30
Real-time Price: $4.66 info
Change: -$6.64 (-59%) info
Market Cap: $378.819M info
PHAT
Jun 23, 2026, 8:03 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $10.64
Real-time Price: $4.66 info
Change: -$5.98 (-56%) info
Market Cap: $378.819M info
PHAT
Jun 23, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.64
Real-time Price: $4.66 info
Change: -$5.98 (-56%) info
Market Cap: $378.819M info
PHAT
Apr 30, 2026, 7:07 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $12.30
Real-time Price: $4.66 info
Change: -$7.64 (-62%) info
Market Cap: $378.819M info
PHAT
Apr 30, 2026, 7:05 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $12.34
Real-time Price: $4.66 info
Change: -$7.68 (-62%) info
Market Cap: $378.819M info
PHAT
Apr 30, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $12.34
Real-time Price: $4.66 info
Change: -$7.68 (-62%) info
Market Cap: $378.819M info
PHAT
Feb 26, 2026, 7:06 AM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $13.42
Real-time Price: $4.66 info
Change: -$8.76 (-65%) info
Market Cap: $378.819M info
PHAT
Feb 26, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $13.42
Real-time Price: $4.66 info
Change: -$8.76 (-65%) info
Market Cap: $378.819M info
PHAT
Jan 08, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.60
Real-time Price: $4.66 info
Change: -$10.94 (-70%) info
Market Cap: $378.819M info
PHAT
Jan 08, 2026, 4:01 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $15.60
Real-time Price: $4.66 info
Change: -$10.94 (-70%) info
Market Cap: $378.819M info
PHAT
Jan 07, 2026, 4:34 PM EST
Filing Type: 424B5
Importance Score:
7
Price at Filing: $15.88
Real-time Price: $4.66 info
Change: -$11.22 (-71%) info
Market Cap: $378.819M info
PHAT
Jan 07, 2026, 4:02 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $18.16
Real-time Price: $4.66 info
Change: -$13.50 (-74%) info
Market Cap: $378.819M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets